Sunrun Inc.

Sunrun Inc. (NASDAQ: RUN)  is home solar, battery storage, and energy services. Residential solar energy systems are designed, developed, installed, sold, owned, and maintained by the company in the United States. It also sells its services to commercial developers through its multi-family and new house offerings, and it offers battery storage and solar energy solutions to customers in select areas.

Key Highlights

• The company reported YoY growth of 109.17% in net revenues to USD 438.77 million in Q3FY21 (ended September 30, 2021) compared to USD 209.76 million in Q3FY20.
• However, due to increased operational expenses, RUN's net loss expanded to USD 241.33 million during Q3FY21 vs. USD 85.40 million in Q3FY20.
• As of September 30, 2021, the company had cash and cash equivalents of USD 717.59 million and total debt of USD 6.16 billion.
• Improvement in gross margin 20.9% in Q3FY21 vs. 18.0% in Q2FY21.
• Its ROE was 0.4% in Q3FY21 vs. the industry median of 3.3%.
• On January 25, 2022, RUN has announced the retirement of its USD 250 million recourse loan facility, favoring a larger USD 425 million facility with better conditions and a longer-term than its previous term extensions.
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, a bearish indicator.
• The stock is leaning towards the lower end of its 52-week range of USD 23.04 to USD 84.81.
• RUN's stock price decreased 55.79% and 52.20% in the past six and nine months, respectively.

Technical Price Chart (as of January 28, 2022). Analysis by Kalkine

Conclusion: Considering the topline growth, long-term profitability issues, technical indicators, and associated risks, we recommend a "Watch" rating on the stock at the closing price of USD 23.42, up 0.64%, as of January 28, 2022.

*The reference data in this report has been partly sourced from REFINITIV.

Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage pharmaceutical company focused on developing and commercializing new treatments for autoimmunity, fibrosis, and cancer that target the endocannabinoid system. Across programs, it produces a diversified pipeline of therapeutic candidates, including small compounds and biologics.

Key Highlights

• The company reported YoY decline of 92.09% in Revenue from awards and licenses to USD 97.32 thousand in Q3FY21 (ended September 30, 2021) compared to USD 1.23 million in Q3FY20 .
• CRBP's net loss reduced to USD 2.18 million during Q3FY21 vs. USD 34.90 million in Q3FY20.
• As of September 30, 2021, the company had cash and cash equivalents of USD 106.86 million and total debt of USD 18.55 million.
• CRBP's Q3FY21 cash cycle of 2,292 days is significantly higher than the industry median of 76 days.
• Its ROE was -2.8% in Q3FY21 vs. the industry median of -7.4%.
• On December 07, 2021, CRBP announced the appointment of Rachael Brake, Ph.D. as its Chief Scientific Officer reinforcing its aim of connecting innovation to purpose.
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, a bearish indicator.
• The stock is leaning towards the lower end of its 52-week range of USD 0.40 to USD 4.00.
• CRBP's stock price decreased 69.77% and 76.99% in the past six and nine months, respectively.

Technical Price Chart (as of January 28, 2022). Analysis by Kalkine

Conclusion: The company's top and bottom-line performance deteriorated in Q3FY21 compared to the previous comparable period. Considering the sharp decline in stock prices, long-term profitability issues, technical indicators, and associated risks, we recommend a "Watch" rating on the stock at the current price of USD 0.4141, up 0.27%, as of January 28, 2022, 03:41 PM ET.

*The reference data in this report has been partly sourced from REFINITIV.